Figure 4.
Proapoptotic synergistic effect of combination of talazoparib with romidepsin in vitro and in vivo. (A) Flow cytometry-based analysis of early (Annexin V+PI−) and late (Annexin V+PI+) apoptosis in MBL2 cells treated with talazoparib alone, romidepsin alone, or talazoparib with romidepsin. (B) Analysis of early and later apoptosis in flow cytometry–based assay (Annexin V and PI) in MBL2 cells treated with talazoparib (T) alone, romidepsin (R) alone, or talazoparib with romidepsin (T+R). ***P < .001, ****P < .0001. (C) Analysis of cell cycle arrest with Click-iT EdU with FxCycle Violet Ready Assay. MBL2 cells treated with talazoparib alone (T), romidepsin (R), or a combination of talazoparib with romidepsin (T+R). (D) The outline of the experiment. (E) The effect of combination of talazoparib and romidepsin on the diameter of regional lymph nodes 24 days after treatment. *P < .05, **P < .01, ****P < .0001. C, control.

Proapoptotic synergistic effect of combination of talazoparib with romidepsin in vitro and in vivo. (A) Flow cytometry-based analysis of early (Annexin V+PI−) and late (Annexin V+PI+) apoptosis in MBL2 cells treated with talazoparib alone, romidepsin alone, or talazoparib with romidepsin. (B) Analysis of early and later apoptosis in flow cytometry–based assay (Annexin V and PI) in MBL2 cells treated with talazoparib (T) alone, romidepsin (R) alone, or talazoparib with romidepsin (T+R). ***P < .001, ****P < .0001. (C) Analysis of cell cycle arrest with Click-iT EdU with FxCycle Violet Ready Assay. MBL2 cells treated with talazoparib alone (T), romidepsin (R), or a combination of talazoparib with romidepsin (T+R). (D) The outline of the experiment. (E) The effect of combination of talazoparib and romidepsin on the diameter of regional lymph nodes 24 days after treatment. *P < .05, **P < .01, ****P < .0001. C, control.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal